Helping patients at risk and living with comorbid chronic conditions

Learn how our comprehensive diagnostic portfolio—coupled with complementary analytical tools—can help you follow guideline-driven testing to identify patients at risk for several cardiometabolic diseases, prevent adverse health outcomes and increase efficiency in your practice.

Address the complexity of identifying and monitoring interrelated conditions

60% of adults in the U.S. are living with a chronic disease—and 4 in 10 U.S. adults are living with two or more chronic diseases—such as diabetes, chronic kidney disease, and cardiovascular disease. These diseases tend to cluster and play a pivotal role in the interaction, development and progression of associated diseases.

  • 33% of diabetic patients have CKD
  • 37% of diabetic patience have Nash
  • Diabetic patients are 2x more likely to have CVD
  • Nearly 40% of persons who have diabetes and more than 30% of those who have hypertension also have CKD.3
  • T2DM patients have a 2 to 3 times higher risk of fatal coronary heart disease.2
  • More than 75% of those who have T2DM have NAFLD.4
  • Cardiovascular disease is the leading cause of death for individuals who have T2DM,6 stage 4-5 CKD,2 and NAFLD.1

Many at-risk patients are not being screened for comorbidities, which are associated with a reduced health-related quality of life, more frequent hospitalization, higher health care costs and increased risk of death.

Manage patients at risk for cardiometabolic diseases and overlapping conditions with our comprehensive testing menu

We understand that managing comorbidities requires complex care. We’re here to help providers identify patients earlier in disease progression, prioritize interventions, weigh risks and benefits in patient treatment plans and better assess quality of care.

Webinar

Two Genetic Causes of Atherosclerosis: Familial Hypercholesterolemia & Elevated Lipoprotein (a)

Moderated by:

Sonal Chandra, MD
Medical Director
MedSci Therapeutic Expertise: Cardiovascular, Metabolic, Neuroscience
Labcorp Drug Development, Inc.

Labcorp test offerings

 

Cardiovascular disease

Lipids and Lipoproteins

Number Name

Emerging Risk Factors and Inflammatory Markers

Number Name

820712 - Lipoprotein associated Phospholipase A2 is also available

Acute Ischemic Markers

Number Name

Genetic Assessment

Number Name

References: 

  1. Lee TA, Shields AE, Vogeli C, Gibson TB, Woong-Sohn M, Marder WD, et al. Mortality rate in veterans with multiple chronic conditions. J Gen Intern Med 2007;22(Suppl 3):403–7.
  2. Statistics About Diabetes. American Diabetes Association. Accessed Sept. 6, 2022. https://www.diabetes.org/resources/statistics/statistics-about-diabetes 
  3.  Deedwania P. Hypertension, dyslipidemia, and insulin resistance in patients with diabetes mellitus or the cardiometabolic syndrome: benefits of vasodilating β-blockers. J Clin Hypertens (Greenwich). 2011 Jan;13(1):52-9. doi: 10.1111/j.1751-7176.2010.00386.x. Epub 2010 Nov 8. PMID: 21214722; PMCID: PMC8672984.
  4. US Preventive Services Task Force. Screening for Prediabetes and Type 2 Diabetes: US Preventive Services Task Force Recommendation Statement. JAMA. 2021;326(8):736– 743. doi:10.1001/jama.2021.12531.